{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005206","form_type":"8-K","ticker":"UG","cik":"0000101295","company_name":"UNITED GUARDIAN INC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.125333+00:00","generated_at":"2026-05-17T16:02:58.919704+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"United-Guardian Q2 net sales fall 16% YoY; EPS $0.14 vs $0.21","bullets":["Q2 net sales $2.84M, down 16% YoY from $3.39M; net income $627K ($0.14) vs $956K ($0.21).","H1 net sales $5.32M, down 20% YoY; net income $1.19M ($0.26) vs $1.88M ($0.41).","Medical lubricants +12% and pharmaceuticals +11% in H1; cosmetic sales fell due to ASI inventory overstock in Asia.","Q2 sequential improvement: sales +14% and net income +12% vs Q1 2025.","Company pursuing Renacidin formulary expansion to boost pharmaceutical sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005206","json":"https://secwatch.observer/filing/0001171843-25-005206.json","markdown":"https://secwatch.observer/filing/0001171843-25-005206.md","text":"https://secwatch.observer/filing/0001171843-25-005206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/101295/000117184325005206/0001171843-25-005206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/101295/000117184325005206/f8k_080725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:02:58.919704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}